First elected: 9th April 1992
Left House: 30th March 2015 (Retired)
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
These initiatives were driven by Glenda Jackson, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Glenda Jackson has not been granted any Urgent Questions
Glenda Jackson has not been granted any Adjournment Debates
Glenda Jackson has not introduced any legislation before Parliament
Glenda Jackson has not co-sponsored any Bills in the current parliamentary sitting
Professor Eileen Munro undertook a wide-ranging independent review of the child protection system in England reporting in 2011. This review looked at the system as a whole, including the adequacy of the child protection legislation. The Department for Education has since clarified the legislation through the revised statutory safeguarding guidance, ‘Working Together to Safeguard Children 2013' so all organisations working with vulnerable children know what the law says they and others must do.
The Department will continue to monitor the current legislation and review options to strengthen the system to keep children safe.
DWP Ministers meet regularly with external organisations in relation to the Department’s work and welfare reform. Details of meetings with external organisations up to and including March 2014 are published by the Cabinet Office as part of the Government’s commitment to transparency, and these details are available at:
http://data.gov.uk/dataset/82fd6446-aa45-4032-9eae-2524a66d8b6b
Information from the remainder of 2014 to February 2015 will be published by the Cabinet Office in due course.
The information requested is shown in the table below.
Outcomes of initial and repeat Employment and Support Allowance (ESA) functional assessments and Incapacity Benefits Reassessments (IBR) by disease code: October 2008 – September 2013
|
| Cystic Fibrosis | Spinal Muscular Atrophy | Parkinson’s Disease | Multiple Sclerosis | Other Rheumatoid Arthritis |
Initial claim | SG | 600 | 900 | 1,100 | 5,200 | 2,100 |
WRAG | 100 | 100 | 700 | 2,500 | 3,100 | |
FFW | 100 | - | 500 | 1,600 | 3,500 | |
Repeat claim | SG | 400 | 200 | 900 | 5,700 | 3,200 |
WRAG | 100 | - | 500 | 2,100 | 3,600 | |
FFW | - | - | 100 | 300 | 1,000 | |
IBR claim | SG | 500 | 200 | 1,100 | 13,400 | 5,000 |
WRAG | 100 | - | 300 | 2,500 | 4,900 | |
FFW | - | - | - | 300 | 1,100 |
Source: Data in the tables above is derived from administrative data held by the DWP and assessment data provided by Atos Healthcare.
Notes:
1. Figures are rounded to the nearest 100. “-“denotes nil or under 50.
2. SG – Support Group
WRAG – Work Related Activity Group
FWW – Fit For Work
3. The outcome recorded is the final DWP Decision Maker’s decision or the recommendation made by the Atos Healthcare Professional where the Decision Maker’s decision is not yet available.
4. Motor neurone disease is shown in the table as 'Spinal muscular atrophy'.
5. The data presented above comes from benefit claims data held by the Department for Work and Pensions. In October 2008, ESA replaced IB for new claims. Starting with a trial in October 2010, and reaching a full scale national roll-out in April 2011, existing IB claims began to be phased out, with claimants reassessed to see if they qualify for ESA instead.
6. The reassessment of existing incapacity benefits claimants was rolled out nationally from April 2011.
The information you requested is commercially sensitive and releasing details of the unit cost of each assessment would, or would be likely to prejudice the commercial interests of Atos Healthcare.
The information requested is shown in the table below.
Number and proportion of repeat functional assessments for Employment and Support Allowance (ESA) claimants by disease code: October 2008 – September 2013
| Cystic Fibrosis | Spinal Muscular Atrophy | Parkinson’s Disease | Multiple Sclerosis | Other Rheumatoid Arthritis |
Number of repeat claims where functional assessment has been completed | 500 | 200 | 1,500 | 8,200 | 7,800 |
Proportion of claimant total; where functional assessment has been completed | 0.04% | 0.02% | 0.13% | 0.68% | 0.65% |
Source: Data in the table above is derived from administrative data held by the DWP and assessment data provided by Atos Healthcare.
Notes:
1. Figures are rounded to the nearest 100. Proportions are shown to 2 decimal places.
2. Motor neurone disease is shown in the table as 'Spinal muscular atrophy'.
3. The data presented above comes from benefit claims data held by the Department for Work and Pensions. In October 2008, ESA replaced IB for new claims. Starting with a trial in October 2010, and reaching a full scale national roll-out in April 2011, existing IB claims began to be phased out, with claimants reassessed to see if they qualify for ESA instead.
Cancer patients are increasingly positive about their care, with 89% rating it as excellent or very good, and this comes as the National Health Service treats more patients for cancer than ever before. The National Cancer Patient Experience Survey results in 2014 show in over half the questions asked, compared to the 2010 survey, patients reporting positively on areas, including feeling they were given enough information, being offered a range of treatment options and being treated with respect and dignity. Where they are telling us we need to do better it is important that swift action is taken and NHS trusts and commissioners must reflect on their results and take action as appropriate.
NHS England is working with NHS Improving Quality and Macmillan Cancer Support to ensure that improvement work is supported by spreading good practice across hospitals providing care in a drive to reduce national variation in patients’ experience of care and raise overall standards, including in London. This includes the experience of care for black and minority ethnic (BME) patients and vulnerable groups.
The Cancer Patient Experience Advisory Group, at its January meeting, will discuss priorities for improvement in cancer patient experience, including for BME patients.
Cancer patients are increasingly positive about their care, with 89% rating it as excellent or very good, and this comes as the National Health Service treats more patients for cancer than ever before. The National Cancer Patient Experience Survey results in 2014 show in over half the questions asked, compared to the 2010 survey, patients reporting positively on areas, including feeling they were given enough information, being offered a range of treatment options and being treated with respect and dignity. Where they are telling us we need to do better it is important that swift action is taken and NHS trusts and commissioners must reflect on their results and take action as appropriate.
NHS England is working with NHS Improving Quality and Macmillan Cancer Support to ensure that improvement work is supported by spreading good practice across hospitals providing care in a drive to reduce national variation in patients’ experience of care and raise overall standards, including in London. This includes the experience of care for black and minority ethnic (BME) patients and vulnerable groups.
The Cancer Patient Experience Advisory Group, at its January meeting, will discuss priorities for improvement in cancer patient experience, including for BME patients.